BEMER MEDICINTECHNIKA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 9,436 | 11,877 | 34,480 | 46,523 | 32,506 | 25,553 | 44,513 | 10,192 |
| Profit before tax | -1,655 | -1,067 | 12,095 | 4,235 | 7,473 | 540 | -7,005 | -9,318 |
| Net profit | -1,655 | -1,067 | 11,951 | 4,235 | 7,099 | 489 | -7,005 | -9,318 |
| Equity | 1,483 | 416 | 12,511 | 16,602 | 23,701 | 24,190 | 17,184 | 7,866 |
| Liabilities | 10,571 | 16,747 | 6,251 | 6,264 | 13,799 | 33,447 | 28,834 | 29,156 |
| Non-current assets | 578 | 312 | 312 | 4,958 | 7,994 | 30,164 | 22,980 | 15,901 |
| Current assets | 11,242 | 16,745 | 18,252 | 17,640 | 29,254 | 22,456 | 22,748 | 21,121 |
| Total assets | 11,820 | 17,057 | 18,564 | 22,598 | 37,248 | 52,620 | 45,728 | 37,022 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 5,909 | 8,452 | 1,173 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +213.0% | +25.9% | +190.3% | +34.9% | -30.1% | -21.4% | +74.2% | -77.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -14.0% | -6.3% | 64.4% | 18.7% | 19.1% | 0.9% | -15.3% | -25.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -111.6% | -256.5% | 95.5% | 25.5% | 30.0% | 2.0% | -40.8% | -118.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -17.5% | -9.0% | 34.7% | 9.1% | 21.8% | 1.9% | -15.7% | -91.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -17.5% | -9.0% | 35.1% | 9.1% | 23.0% | 2.1% | -15.7% | -91.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 7.1 | 40.3 | 0.5 | 0.4 | 0.6 | 1.4 | 1.7 | 3.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 9,436 | 11,877 | 34,480 | 46,523 | 32,506 | 25,553 | 44,513 | 10,192 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
BEMER MEDICINTECHNIKA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-12-18 | 2024-01-11 | 0.02 |
| 2023-11-16 | 2023-12-14 | 0.02 |
| 2023-10-17 | 2023-11-12 | 0.02 |
| 2023-09-18 | 2023-10-15 | 0.02 |
| 2023-08-17 | 2023-09-14 | 0.02 |
| 2023-07-28 | 2023-08-13 | 0.02 |
| 2023-07-24 | 2023-07-25 | 0.02 |
| 2023-06-16 | 2023-06-18 | 13.71 |
| 2023-05-16 | 2023-05-17 | 8.19 |
| 2022-05-17 | 2022-05-18 | 12.78 |
BEMER MEDICINTECHNIKA - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
BEMER MEDICINTECHNIKA, UAB (code 300025608) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €10.2K, down 77.1% year on year and 60.1% over two years. Net profit for 2025 was a loss of €9.3K, compared with a profit of €489 in 2023 and a loss of €7.0K in 2024, showing a clear deterioration in profitability. The 2025 balance sheet shows total assets of €37.0K, equity of €7.9K and liabilities of €29.2K. Equity has weakened from €24.2K in 2023 and €17.2K in 2024, while liabilities remained close to the €29K level. Long-term assets declined from €30.2K in 2023 to €15.9K in 2025, while short-term assets were €21.1K. The company’s financial ratios point to pressure on capital efficiency and leverage, with a debt-to-equity ratio of 3.71 and an equity ratio of 21.2%. Revenue per employee was €10.2K, indicating limited operating scale in 2025.